Luxendo, a startup launched by the European Molecular Biology Laboratory (EMBL) and its technology transfer arm EMBLEM Technology Transfer (EMBLEM) in Heidelberg, Germany, closed a €6M Series A financing.
The round was co-led by EMBL Ventures and Life Science Partners (LSP), Amsterdam. In conjunction with the funding, Dr Stefan Herr, Partner at EMBL Ventures and Dr. Joachim Rothe, Partner at LSP will join Luxendo’s Board.
Luxendo will manufacture and sell advanced Single Plane Illumination Microscopes (SPIM) originally developed at EMBL by Lars Hufnagel and his team. SPIM is an emerging technology that combines optical sectioning with multiple-view imaging to observe tissues and living organisms with high resolution.
According to a note, when compared to conventional microscopy, the SPIM technology allows for significantly reduced sampling times (factor 1000x) and higher resolution with highly reduced damaging side effects on the living objects.